Cannabis News and Research

Latest Cannabis News and Research

Cannabis abuse in FEP patients predicts poor symptom control

Patients with first-episode psychosis and comorbid cannabis abuse are at high risk for poor symptom control even when on medication, suggest findings published in Schizophrenia Research.

1 Oct 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Endocannabinoids may contribute to pregnancy complications

New research indicates marijuana-like compounds called endocannabinoids alter genes and biological signals critical to the formation of a normal placenta during pregnancy and may contribute to pregnancy complications like preeclampsia.

13 Sep 2012

SUDs common in youth at high risk for bipolar disorder

Around a quarter of young people at high risk for mood disorders have a substance use disorder, results from a Canadian study suggest.

12 Sep 2012

Roundup: Brown's pension plan no panacea for Calif.; Personhood amendment won't make Colo. ballot

Even by the most ambitious forecasts, the plan Gov. Jerry Brown and fellow Democrats are championing to contain government worker pensions in California could leave state taxpayers awash in debt to public employees.

31 Aug 2012

Early cannabis use damages developing brain

Persistent use of cannabis before the age of 18 years can lead to lowered intelligence, attention, and memory in adulthood, show results published in the Proceedings of the National Academy of Sciences.

30 Aug 2012

Impulsiveness linked to bipolar disorder severity

Trait impulsiveness is associated with a severe course of bipolar disorder, researchers report.

21 Aug 2012

CBIS initiates CS-TATI-1 GMP development plan

Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical to meet global public health challenges is pleased to announce the initiation of GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma.

13 Aug 2012

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

Strong oppositional behaviors associated with drug abuse among children

Children who exhibit oppositional behavior run the risk of becoming addicted to nicotine, cannabis and cocaine whilst Inattention symptoms represent a specific additional risk of nicotine addiction. Nevertheless, hyperactivity in itself does not seem to be associated with any specific risk of substance abuse or dependence.

2 Aug 2012

Scientists analyze raw sewage samples to determine illicit drug use

Surveys of drug use form an important basis for the development of effective drug policies, and also for measuring the effectiveness of existing policies. For the first time in history, scientists have now made direct comparisons of illicit drug use in 19 European cities by a cooperative analysis of raw sewage samples.

27 Jul 2012

Cannabis use linked to cognitive performance in bipolar patients

Results from a US study suggest that bipolar I disorder patients with a history of cannabis use have better neurocognitive function than those who have not used cannabis.

20 Jul 2012

Researchers identify cannabinoid-making pathway

U of S researchers have discovered the chemical pathway that Cannabis sativa uses to create bioactive compounds called cannabinoids, paving the way for the development of marijuana varieties to produce pharmaceuticals or cannabinoid-free industrial hemp.

17 Jul 2012

Cannabis use may reduce mortality risk in psychosis patients

Cannabis use is associated with reduced mortality risk in patients with psychotic disorders, study results suggest.

10 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Study finds no evidence to support an effect of THC on MS progression

The first large non-commercial study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS) shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

16 Jun 2012

Experimental drug and genetic differences indicate how people deal with fear and stress

Researchers at Duke University and the National Institutes of Health have found a way to calm the fears of anxious mice with a drug that alters their brain chemistry. They've also found that human genetic differences related to the same brain chemistry influence how well people cope with fear and stress.

12 Jun 2012

MARIJUANA announces corporate name change to Hemp

MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.

4 Jun 2012

Latest results from Youth Smoking Survey

According to the latest results of the Youth Smoking Survey, only three per cent of Canadian students in grades 6-12 said they smoked daily in 2010-2011, down from 4% in 2008-2009.

2 Jun 2012

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spending

After an exhaustive process, the U.S. Preventive Services Task Force has announced its final recommendation on PSA-based prostate cancer screening. It finds that the known harms of screening outweigh the potential benefits for men who have no cancer symptoms. It notes that all screening studies have demonstrated considerable harms associated with screening, but only one major study found evidence that screening saves lives -- and that study has some internal inconsistencies.

24 May 2012